This bill mandates the establishment and maintenance of a preferred drug list by the Division of Medical Assistance and Health Services for the New Jersey Medicaid program. The preferred drug list will include both drug and non-drug items selected based on their clinical and economic merits, with all products subject to utilization management, including prior authorization. The division is granted the authority to negotiate supplemental rebates with drug manufacturers, which are separate from federal rebates, to help control drug costs while improving care quality and health outcomes. Managed care organizations are prohibited from negotiating rebates on these products, and the division will retain final authority over all pharmacy services.

Additionally, the bill outlines specific requirements for pharmacy benefits managers, prohibiting them from negotiating or retaining manufacturer rebates on preferred drugs and limiting their income to fees agreed upon with payers. The bill also mandates the collection and maintenance of detailed financial information related to the preferred drug list, including income sources and ingredient costs. The Drug Utilization Review Board's role is expanded to include clinical reviews and recommendations for the preferred drug list, while ensuring that all final decisions remain with the division. Overall, the bill aims to enhance the efficiency and effectiveness of the Medicaid drug management system in New Jersey.